CXCL12 and B-cell chronic lymphocytic leukemia: The therapeutic potential for targeting LYN and HS1 in CLL has been assessed in TCL1-tg transplantable mouse model.79In vitro treatment with the tyrosine kinase inhibitor, dasatinib, prevents HS1 and ERK phosphorylation, induces apoptosis and blocks CXCL12 chemotaxis and the interaction with stromal cells.